Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study

Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study

Abstract Background Patients with diabetes and acute coronary syndrome (ACS) are at high risk for subsequent heart failure. Apabetalone is a selective inhibitor of bromodomain and extra-terminal (BET) proteins, epigenetic regulators of gene expression. Preclinical data suggest that apabetalone exert...

Full description

Bibliographic Details
Main Authors: Stephen J. Nicholls, Gregory G. Schwartz, Kevin A. Buhr, Henry N. Ginsberg, Jan O. Johansson, Kamyar Kalantar-Zadeh, Ewelina Kulikowski, Peter P. Toth, Norman Wong, Michael Sweeney, Kausik K. Ray, the BETonMACE Investigators
Format: Article
Language:English
Published: BMC 2021-01-01
Series:Cardiovascular Diabetology
Subjects:
BET inhibitors
Acute coronary syndrome
Diabetes
Heart failure
Clinical trial
Cardiovascular disease
Online Access:https://doi.org/10.1186/s12933-020-01199-x

Internet

https://doi.org/10.1186/s12933-020-01199-x

Similar Items